Target Price | €184.60 |
Price | €137.85 |
Potential | 33.91% |
Number of Estimates | 15 |
15 Analysts have issued a price target Merck 2025 . The average Merck target price is €184.60. This is 33.91% higher than the current stock price. The highest price target is €199.00 44.36% , the lowest is €160.00 16.07% . | |
A rating was issued by 17 analysts: 14 Analysts recommend Merck to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2025 of 33.91% . Most analysts recommend the Merck stock at Purchase. |
14 Analysts have issued a sales forecast Merck 2024 . The average Merck sales estimate is €21.1b . This is 0.75% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €21.3b 1.42% , the lowest is €21.0b 0.00% .
This results in the following potential growth metrics:
2023 | €21.0b | 5.57% |
---|---|---|
2024 | €21.1b | 0.61% |
2025 | €22.1b | 4.60% |
2026 | €23.1b | 4.52% |
2027 | €24.1b | 4.41% |
2028 | €25.3b | 4.82% |
14 Analysts have issued an Merck EBITDA forecast 2024. The average Merck EBITDA estimate is €6.0b . This is 6.29% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €6.1b 4.55% , the lowest is €5.8b 9.52% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | €5.8b | 14.26% |
---|---|---|
2024 | €6.0b | 3.41% |
2025 | €6.5b | 8.17% |
2026 | €7.0b | 6.77% |
2027 | €7.3b | 4.74% |
2028 | €7.8b | 6.42% |
2023 | 27.75% | 9.20% |
---|---|---|
2024 | 28.52% | 2.78% |
2025 | 29.49% | 3.40% |
2026 | 30.13% | 2.17% |
2027 | 30.23% | 0.33% |
2028 | 30.69% | 1.52% |
12 Merck Analysts have issued a net profit forecast 2024. The average Merck net profit estimate is €2.9b . This is 8.39% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.1b 16.13% , the lowest is €2.8b 4.35% .
This results in the following potential growth metrics and future Net Margins:
2023 | €2.8b | 15.03% |
---|---|---|
2024 | €2.9b | 3.39% |
2025 | €3.4b | 17.62% |
2026 | €3.7b | 9.01% |
2027 | €4.1b | 8.13% |
2028 | €4.4b | 9.14% |
2023 | 13.46% | 10.02% |
---|---|---|
2024 | 13.83% | 2.73% |
2025 | 15.56% | 12.51% |
2026 | 16.22% | 4.24% |
2027 | 16.80% | 3.58% |
2028 | 17.50% | 4.17% |
12 Analysts have issued a Merck forecast for earnings per share. The average Merck <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is €6.72 . This is 8.39% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is €7.20 16.13% , the lowest is €6.47 4.35% .
This results in the following potential growth metrics and future valuations:
2023 | €6.50 | 15.03% |
---|---|---|
2024 | €6.72 | 3.38% |
2025 | €7.90 | 17.56% |
2026 | €8.62 | 9.11% |
2027 | €9.32 | 8.12% |
2028 | €10.17 | 9.12% |
Current | 22.23 | 4.71% |
---|---|---|
2024 | 20.51 | 7.74% |
2025 | 17.44 | 14.97% |
2026 | 16.00 | 8.26% |
2027 | 14.80 | 7.50% |
2028 | 13.56 | 8.38% |
Based on analysts' sales estimates for 2024, the Merck stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 3.23 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 2.84 .
This results in the following potential growth metrics and future valuations:
Current | 3.26 | 0.31% |
---|---|---|
2024 | 3.23 | 0.90% |
2025 | 3.09 | 4.40% |
2026 | 2.96 | 4.33% |
2027 | 2.83 | 4.22% |
2028 | 2.70 | 4.60% |
Current | 2.86 | 0.28% |
---|---|---|
2024 | 2.84 | 0.75% |
2025 | 2.71 | 4.40% |
2026 | 2.60 | 4.33% |
2027 | 2.49 | 4.22% |
2028 | 2.37 | 4.60% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.